Steven M Smoke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9501946/publications.pdf Version: 2024-02-01



STEVEN M SMOKE

#	Article	IF	CITATIONS
1	Realâ€world evaluation of the impact of two antiâ€SARSâ€CoVâ€2 monoclonal antibody regimens on COVIDâ€19 hospitalizations in older adults. Journal of Medical Virology, 2022, , .	9 5.0	3
2	Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study. International Journal of Antimicrobial Agents, 2021, 57, 106265.	2.5	6
3	The DOOR to Antibiotic Stewardship: Refining Assessments of Interventions With Desirability of Outcome Ranking. Journal of Pharmacy Practice, 2021, , 089719002098713.	1.0	0
4	Save the Quinolones! Impact of a Non-Restrictive Fluoroquinolone Reduction Initiative on Antibiotic Use and Resistance at an Urban Teaching Hospital. Journal of Pharmacy Practice, 2021, , 089719002110034.	1.0	0
5	Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVIDâ€19. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1308-1311.	1.5	4
6	1291. PROVE (Retrospective Cefiderocol Chart Review) Study of Real-World Outcomes and Safety in the Treatment of Patients with Gram-negative Bacterial Infections in the US and Europe. Open Forum Infectious Diseases, 2021, 8, S734-S735.	0.9	0
7	132. Standardized Antimicrobial Administration Ratios to Guide Antimicrobial Stewardship in the Neonatal Intensive Care Unit: a Single Center Experience. Open Forum Infectious Diseases, 2021, 8, S178-S179.	0.9	Ο
8	186. Prescriber-Led Antibiotic Timeout Alert Responses: A Retrospective Multicenter Study. Open Forum Infectious Diseases, 2020, 7, S99-S99.	0.9	0
9	554. Early Clinical Outcomes with Tocilizumab for Covid-19: A Two-Center Retrospective Study. Open Forum Infectious Diseases, 2020, 7, S342-S343.	0.9	Ο
10	Selective antibiotic susceptibility reporting and broad-spectrum intravenous antibiotic use: A multicentre ecological study. International Journal of Antimicrobial Agents, 2019, 54, 367-370.	2.5	3
11	144. Organism Identification and Antibiotic Susceptibilities with Verigene Blood Culture Assay: a Retrospective Single-Center Study. Open Forum Infectious Diseases, 2019, 6, S99-S100.	0.9	Ο
12	1005. The Antibiotic Optimization DOOR: Refining Assessment of Antibiotic Therapy with Desirability of Outcome Ranking. Open Forum Infectious Diseases, 2019, 6, S354-S354.	0.9	0
13	Antibiotic Decision-Making Among Medical Residents, Medical Students, and Nurse Practitioners: A Single-Center Survey. Journal of Pharmacy Practice, 2019, 32, 372-374.	1.0	3
14	Effect of Carbapenem Selection on Drug Acquisition Costs and Carbapenem Resistance. Journal of Pharmacy Practice, 2019, 32, 7-8.	1.0	0
15	221. Save the Quinolones! Impact of a Non-Restrictive Fluoroquinolone Reduction Initiative on Antibiotic Resistance at an Urban Teaching Hospital. Open Forum Infectious Diseases, 2018, 5, S96-S96.	0.9	0
16	Effect of Leadership Commitment and Education on Antimicrobial Use and Hospital-Acquired Clostridium difficile infection rates at a Community Hospital. Open Forum Infectious Diseases, 2017, 4, S262-S262.	0.9	0